IL-CG-LIFE
5.1.2023 14:01:43 CET | Business Wire | Press release
CG Life, an integrated digital marketing and public relations agency supporting life science and healthcare companies, and MC Services AG, a major European public relations and investor relations firm with a similar life sciences focus, announced today a strategic partnership between the agencies. The two companies have created an integrated service platform for biotech and pharmaceutical companies to extend their reach and access more easily to capital, talent, and business audiences on both sides of the Atlantic. Both firms will remain fully and legally independent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005125/en/
For MC Services, this partnership provides an industry-respected gateway for accessing marketing, branding, digital marketing, public relations, and advertising capabilities in the U.S. And as CG Life’s clients increasingly request global capabilities across PR, branding, paid media, and more, CG Life will be able to activate a highly experienced communications and investor relations team in Europe and in Germany, in particular—the largest European healthcare market.
“Accessing the U.S. market is vital for the European biopharma sector, and we have worked for many years to better connect our clients to the life science ecosystem in the States,” said Raimund Gabriel, Managing Partner of MC Services. “We are excited to continue that mission by establishing a strategic alliance with CG Life, a like-minded agency in the U.S. with a global view that is equally committed to quality and performance.”
“Through extensive discussion, analysis, and reflection, both agency teams recognized that we share very similar cultural values, commitment to our clients and science, and an emphasis on providing business solutions rather than just delivering services,” said CG Life Managing Partner Erik Clausen. “We couldn’t be happier that we found a partner in MC Services that has the experience, skill and mindset, and relationships to collaborate with us and our clients.”
About MC Services AG
MC Services AG is an international public relations and investor relations firm specializing in communications for the life sciences and healthcare sectors. A strong team of science, finance, media, and communication experts, with extensive industry experience, positions MC Services as a leading life sciences agency in Europe.
MC Services' long-standing clients include international public and private companies, as well as venture capitalists and investment firms. Established for many years as a link between the healthcare industry and the financial markets, MC Services provides comprehensive services in investor relations, public relations, and financial transactions. MC Services is based in Munich, Düsseldorf, Berlin, London, and Boston. www.mc-services.eu
About CG Life
Propelled by science since 2003, CG Life’s mission is to celebrate scientific discoveries and medical innovations through personal and impactful brand experiences. The team integrates smart strategies, inspirational creativity, insightful content, clever communications, and digital platforms to create and elevate leading and disruptive science and healthcare brands. CG Life supports emerging science and technology organizations through The Market Element, a CG Life Agency. Connect with CG Life on LinkedIn, Twitter, Instagram or Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005125/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom